News
Following are announcements of notable deals and cases on which Davis Polk has advised, as well as a range of other news items about the firm and our lawyers.
| April 12, 2021 | Diagnósticos da América R$3.3 billion equity offering We advised the global coordinators and joint bookrunners on the Rule 144A / Regulation S offering | |
| April 12, 2021 | Ionis Pharmaceuticals $632.5 million convertible senior notes offering We advised the purchasers on the Rule 144A convertible notes offering | |
| April 12, 2021 | Maravai LifeSciences $646.9 million secondary offering We advised the joint book-running managers on the equity offering | |
| April 1, 2021 | Beam Therapeutics $300 million at-the-market offering We advised the sales agent in connection with the equity offering | |
| March 30, 2021 | LAVA Therapeutics $100.5 million IPO We advised the underwriters on the IPO and Nasdaq listing | |
| March 30, 2021 | Alignment Healthcare $489.6 million IPO We advised the underwriters on the IPO and Nasdaq listing | |
| March 26, 2021 | Gyroscope Therapeutics $148.0 million Series C equity financing We advised Gyroscope Therapeutics on its private placement of preferred stock | |
| March 24, 2021 | Solid Biosciences $143.75 million follow-on equity offering We advised the joint book-running managers on the stock offering | |
| March 24, 2021 | Charles River Laboratories International $1 billion senior notes offering We advised Charles River Laboratories on the high-yield debt offering | |
| March 23, 2021 | Connect Biopharma $219.9 million IPO We advised the underwriters on the IPO and Nasdaq listing | |
- 1 of 61
- next ›
News
News Search: